Literature DB >> 27392033

Facial manifestations of Epstein-Barr virus-related lymphoproliferative disease in childhood acute lymphoblastic leukemia in remission: Two atypical presentations.

Benjamin Y Lu1, Lisa Kojima2, Mary S Huang1, Alison M Friedmann1, Judith A Ferry3, Howard J Weinstein4.   

Abstract

Epstein-Barr virus-related lymphoproliferative disease (EBV-LPD) rarely occurs in patients with acute lymphoblastic leukemia (ALL), who have not received hematopoietic transplantation. We describe EBV-LPD manifesting as facial lesions in two children with ALL in remission. One patient was a 16-year-old male with T-cell ALL with an EBV-positive angiocentric polymorphous lip lesion presenting as right-sided facial swelling. The other patient was a 12-year-old male with B-cell ALL with an EBV-positive polymorphous lymphoplasmacytic infiltrate presenting as bilateral dacryoadenitis. Neither patient had known primary immunodeficiencies. Both cases improved with immunosuppressant de-escalation. These cases suggest that immunosuppression induced by maintenance chemotherapy is sufficient to promote EBV-LPD.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Epstein-Barr virus; acute lymphoblastic leukemia; lymphoproliferative disease; maintenance chemotherapy

Mesh:

Year:  2016        PMID: 27392033     DOI: 10.1002/pbc.26102

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

Review 1.  Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases.

Authors:  Jean de Melo Silva; Renato Pinheiro-Silva; Anamika Dhyani; Gemilson Soares Pontes
Journal:  Biomed Res Int       Date:  2020-10-24       Impact factor: 3.411

2.  Case Report: Multifocal EBV-Associated Diffuse Large B-Cell Lymphoma in a Patient With 6-MP Associated Lymphopenia With TPMT Deficiency.

Authors:  Lara Müller-Scholden; Frank Deinlein; Matthias Eyrich; Paul Gerhardt Schlegel; Verena Wiegering; Matthias Wölfl
Journal:  Front Pediatr       Date:  2022-05-06       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.